Education
About Us
Working with TipRanks
Follow Us
Emergent Biosolutions (EBS)
NYSE:EBS
EBS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.02 - $12.73
Previous CloseN/A
Volume114.70K
Average Volume (3M)1.32M
Market Cap
$442.81M
Enterprise Value$750.90M
Total Cash (Recent Filing)$149.10M
Total Debt (Recent Filing)$665.70M
Price to Earnings (P/E)3.3
Beta3.22
Next Earnings
Nov 05, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding53,351,097
10 Day Avg. Volume1,038,107
30 Day Avg. Volume1,315,975
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit2.47
Enterprise Value/Ebitda7.06
Forecast
1Y Price Target
$13.50Price Target Upside72.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Contract AwardsEmergent announced that it has received a $30M contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply CYFENDUS.
Financial PerformanceEmergent also continued to make strides in improving its balance sheet, bolstered by $95 million in operating cash flow to date this year, helping the Company reduce its net debt to $433 million at the end of the second quarter.
Market ExpansionEmergent recently announced a $65M multi-year contract with Ontario Ministry of Health for NARCAN Nasal Spray.
Bears Say
Generic CompetitionRisks include faster-than-anticipated NARCAN franchise erosion due to greater-than-anticipated levels of generic competition.
Revenue MissEmergent recorded $140.9M in total top-line revenue, which missed the forecast of $192.1M.
Emergent Biosolutions News
EBS FAQ
What was Emergent Biosolutions’s price range in the past 12 months?
Emergent Biosolutions lowest stock price was $4.02 and its highest was $12.73 in the past 12 months.
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is $442.81M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s upcoming earnings report date is Nov 05, 2025 which is in 62 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Aug 06, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of -$0.413 by $0.573.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions does not currently pay dividends.
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is 0.05.
How many shares outstanding does Emergent Biosolutions have?
Emergent Biosolutions has 53,351,097 shares outstanding.
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of $0.16 in its last earnings report, beating expectations of -$0.413. Following the earnings report the stock price went up 36.65%.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Currently, no hedge funds are holding shares in EBS
Emergent Biosolutions Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (72.41% Upside)
$13.50 (72.41% Upside)
Blogger Sentiment
Bullish
EBS Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $67.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.20%
12-Months-Change
Fundamentals
Return on Equity
30.24%
Trailing 12-Months
Asset Growth
-6.37%
Trailing 12-Months
Company Description
Emergent Biosolutions
Emergent BioSolutions (EBS) is a global life sciences company focused on providing specialized products and services to address public health needs, particularly in the areas of biodefense, infectious disease, and healthcare. The company operates through two primary segments: Biodefense and Commercial, offering a range of products including vaccines, therapeutics, and diagnostics. EBS is known for its expertise in developing and manufacturing biologics and pharmaceuticals that protect against biological threats and diseases.
EBS Company Deck
EBS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Emergent, with significant financial improvements, increased guidance, and strong performance in international sales and NARCAN revenue. However, there were some declines in specific product sales and a decrease in revenue compared to the first half of 2024, which are being managed through strategic initiatives.View all EBS earnings summariesEBS Stock 12 Month Forecast
Average Price Target
$13.50
▲(72.41% Upside)
Technical Analysis
Dynavax
―
Lifecore Biomedical
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Aquestive Therapeutics
―
Ownership Overview
4.04% Insiders
11.66% Mutual Funds
19.00% Other Institutional Investors
43.27% Public Companies and
Individual Investors